Financial Contrast: BioSig Technologies (BSGM) vs. Its Peers

BioSig Technologies (OTCMKTS: BSGM) is one of 46 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its rivals? We will compare BioSig Technologies to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, profitability, earnings, risk and dividends.

Volatility & Risk

How to Become a New Pot Stock Millionaire

BioSig Technologies has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, BioSig Technologies’ rivals have a beta of 1.58, indicating that their average stock price is 58% more volatile than the S&P 500.

Earnings and Valuation

This table compares BioSig Technologies and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioSig Technologies N/A -$12.69 million -3.62
BioSig Technologies Competitors $1.10 billion $121.39 million -37.94

BioSig Technologies’ rivals have higher revenue and earnings than BioSig Technologies. BioSig Technologies is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares BioSig Technologies and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioSig Technologies N/A N/A -1,090.30%
BioSig Technologies Competitors -207.45% 32.88% -13.47%

Insider and Institutional Ownership

0.1% of BioSig Technologies shares are owned by institutional investors. Comparatively, 41.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 44.9% of BioSig Technologies shares are owned by insiders. Comparatively, 20.1% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for BioSig Technologies and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioSig Technologies 0 0 1 0 3.00
BioSig Technologies Competitors 147 434 967 26 2.55

As a group, “Electromedical equipment” companies have a potential upside of 21.90%. Given BioSig Technologies’ rivals higher possible upside, analysts plainly believe BioSig Technologies has less favorable growth aspects than its rivals.

Summary

BioSig Technologies rivals beat BioSig Technologies on 8 of the 13 factors compared.

About BioSig Technologies

BioSig Technologies, Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company’s PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms, and helps in making clinical decisions in real-time. It is also developing signal-processing tools, which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System.

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Capital One Financial Weighs in on Cousins Properties’ Q3 2018 Earnings
Capital One Financial Weighs in on Cousins Properties’ Q3 2018 Earnings
Royal Gold  Forecasted to Post Q3 2018 Earnings of $0.42 Per Share
Royal Gold Forecasted to Post Q3 2018 Earnings of $0.42 Per Share
Campbell Soup  Forecasted to Post Q3 2018 Earnings of $0.60 Per Share
Campbell Soup Forecasted to Post Q3 2018 Earnings of $0.60 Per Share
Infineon Technologies  PT Set at €28.00 by Goldman Sachs
Infineon Technologies PT Set at €28.00 by Goldman Sachs
Hauck & Aufhaeuser Reiterates €16.50 Price Target for Hamburger Hafen und Logistik
Hauck & Aufhaeuser Reiterates €16.50 Price Target for Hamburger Hafen und Logistik
Drägerwerk  Earns “Neutral” Rating from Deutsche Bank
Drägerwerk Earns “Neutral” Rating from Deutsche Bank


Leave a Reply

© 2006-2018 Ticker Report. Google+.